By UCI Health News –
The California Institute for Regenerative Medicine (CIRM) has awarded a UC Irvine neuroscientist $4.6 million to advance studies of a novel immunotherapy that holds the potential to revolutionize cancer treatment by targeting all major cancer types.
The grant for $4,581,144 was awarded to Michael Demetriou, MD, PhD, to accelerate his lab’s groundbreaking work on genetically modified chimeric antigen receptor (CAR) T cells that can destroy tumors by attacking abnormal complex sugar chains called glycans found on the surface of all major cancer cell types.
